Aralez Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenues, net of USD 38,081,000 against USD 25,969,000 a year ago. Loss from operations was USD 14,069,000 against USD 20,683,000 a year ago. Loss before income taxes was USD 20,939,000 against USD 26,925,000 a year ago. Net loss was USD 19,741,000 or USD 0.29 per basic and diluted share against USD 27,477,000 or USD 0.42 per basic and diluted share a year ago. Adjusted EBITDA was USD 4,928,000 against Adjusted LBITDA of USD 3,642,000 a year ago.